nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Sudden death—Teniposide—lymphatic system cancer	0.0366	0.0366	CcSEcCtD
Lisdexamfetamine—Digestion impaired—Fludarabine—lymphatic system cancer	0.0246	0.0246	CcSEcCtD
Lisdexamfetamine—Cardiomyopathy—Mitoxantrone—lymphatic system cancer	0.0191	0.0191	CcSEcCtD
Lisdexamfetamine—Sudden death—Mitoxantrone—lymphatic system cancer	0.0191	0.0191	CcSEcCtD
Lisdexamfetamine—Depression—Mechlorethamine—lymphatic system cancer	0.0142	0.0142	CcSEcCtD
Lisdexamfetamine—Aggression—Bleomycin—lymphatic system cancer	0.0137	0.0137	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Fludarabine—lymphatic system cancer	0.0126	0.0126	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Lisdexamfetamine—Sudden death—Methotrexate—lymphatic system cancer	0.00954	0.00954	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00939	0.00939	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00913	0.00913	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00908	0.00908	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00906	0.00906	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00903	0.00903	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00894	0.00894	CcSEcCtD
Lisdexamfetamine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0088	0.0088	CcSEcCtD
Lisdexamfetamine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00864	0.00864	CcSEcCtD
Lisdexamfetamine—Visual impairment—Fludarabine—lymphatic system cancer	0.00797	0.00797	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00788	0.00788	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00782	0.00782	CcSEcCtD
Lisdexamfetamine—Diplopia—Carmustine—lymphatic system cancer	0.00765	0.00765	CcSEcCtD
Lisdexamfetamine—Agitation—Teniposide—lymphatic system cancer	0.00752	0.00752	CcSEcCtD
Lisdexamfetamine—Malnutrition—Fludarabine—lymphatic system cancer	0.0072	0.0072	CcSEcCtD
Lisdexamfetamine—Hypertension—Teniposide—lymphatic system cancer	0.00707	0.00707	CcSEcCtD
Lisdexamfetamine—Weight decreased—Bleomycin—lymphatic system cancer	0.00685	0.00685	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00668	0.00668	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00666	0.00666	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00662	0.00662	CcSEcCtD
Lisdexamfetamine—Agitation—Fludarabine—lymphatic system cancer	0.00661	0.00661	CcSEcCtD
Lisdexamfetamine—Tachycardia—Teniposide—lymphatic system cancer	0.00652	0.00652	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00649	0.00649	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00646	0.00646	CcSEcCtD
Lisdexamfetamine—Anorexia—Teniposide—lymphatic system cancer	0.00637	0.00637	CcSEcCtD
Lisdexamfetamine—Convulsion—Fludarabine—lymphatic system cancer	0.00624	0.00624	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0062	0.0062	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Teniposide—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Lisdexamfetamine—Depression—Carmustine—lymphatic system cancer	0.00588	0.00588	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Teniposide—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Lisdexamfetamine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Lisdexamfetamine—Rash—Mechlorethamine—lymphatic system cancer	0.00572	0.00572	CcSEcCtD
Lisdexamfetamine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00571	0.00571	CcSEcCtD
Lisdexamfetamine—Weight decreased—Vincristine—lymphatic system cancer	0.00571	0.00571	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Lisdexamfetamine—Depression—Vincristine—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Lisdexamfetamine—Anorexia—Fludarabine—lymphatic system cancer	0.0056	0.0056	CcSEcCtD
Lisdexamfetamine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00559	0.00559	CcSEcCtD
Lisdexamfetamine—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Vincristine—lymphatic system cancer	0.00551	0.00551	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Lisdexamfetamine—Nausea—Mechlorethamine—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Lisdexamfetamine—Urticaria—Teniposide—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Teniposide—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Lisdexamfetamine—Hallucination—Carmustine—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Lisdexamfetamine—Visual impairment—Carmustine—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Lisdexamfetamine—Fatigue—Fludarabine—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Lisdexamfetamine—Hallucination—Vincristine—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Lisdexamfetamine—Constipation—Fludarabine—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Lisdexamfetamine—Eye disorder—Carmustine—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Lisdexamfetamine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Lisdexamfetamine—Asthenia—Teniposide—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Lisdexamfetamine—Mental disorder—Carmustine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Lisdexamfetamine—Malnutrition—Carmustine—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Teniposide—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Lisdexamfetamine—Mental disorder—Vincristine—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Lisdexamfetamine—Vision blurred—Carmustine—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Lisdexamfetamine—Tremor—Carmustine—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Lisdexamfetamine—Vomiting—Teniposide—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Lisdexamfetamine—Agitation—Carmustine—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Lisdexamfetamine—Asthenia—Fludarabine—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Lisdexamfetamine—Rash—Teniposide—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Lisdexamfetamine—Dermatitis—Teniposide—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Lisdexamfetamine—Headache—Teniposide—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Lisdexamfetamine—Anorexia—Bleomycin—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Lisdexamfetamine—Agitation—Vincristine—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Lisdexamfetamine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Lisdexamfetamine—Convulsion—Carmustine—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Lisdexamfetamine—Hypertension—Carmustine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Lisdexamfetamine—Nausea—Teniposide—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Lisdexamfetamine—Anxiety—Carmustine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Lisdexamfetamine—Convulsion—Vincristine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Lisdexamfetamine—Hypertension—Vincristine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Methotrexate—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Lisdexamfetamine—Vomiting—Fludarabine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Lisdexamfetamine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Lisdexamfetamine—Rash—Fludarabine—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Lisdexamfetamine—Dermatitis—Fludarabine—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Lisdexamfetamine—Hypertension—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Lisdexamfetamine—Headache—Fludarabine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Lisdexamfetamine—Tachycardia—Carmustine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Lisdexamfetamine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Lisdexamfetamine—Anorexia—Carmustine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Lisdexamfetamine—Nausea—Fludarabine—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Lisdexamfetamine—Urticaria—Bleomycin—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Lisdexamfetamine—Anorexia—Vincristine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Lisdexamfetamine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Bleomycin—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Lisdexamfetamine—Insomnia—Carmustine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Lisdexamfetamine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Lisdexamfetamine—Irritability—Methotrexate—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Carmustine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Lisdexamfetamine—Somnolence—Carmustine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Lisdexamfetamine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Carmustine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Lisdexamfetamine—Insomnia—Vincristine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Lisdexamfetamine—Constipation—Carmustine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Vincristine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Lisdexamfetamine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Lisdexamfetamine—Fatigue—Vincristine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Lisdexamfetamine—Asthenia—Bleomycin—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Lisdexamfetamine—Constipation—Vincristine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Lisdexamfetamine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Lisdexamfetamine—Constipation—Mitoxantrone—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Lisdexamfetamine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Lisdexamfetamine—Vomiting—Bleomycin—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Lisdexamfetamine—Depression—Methotrexate—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Lisdexamfetamine—Rash—Bleomycin—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Lisdexamfetamine—Dermatitis—Bleomycin—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Lisdexamfetamine—Asthenia—Carmustine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Lisdexamfetamine—Asthenia—Vincristine—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Carmustine—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Lisdexamfetamine—Nausea—Bleomycin—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Lisdexamfetamine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Lisdexamfetamine—Dizziness—Carmustine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Lisdexamfetamine—Hepatitis—Methotrexate—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Lisdexamfetamine—Vomiting—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Lisdexamfetamine—Dizziness—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Lisdexamfetamine—Rash—Carmustine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Lisdexamfetamine—Dermatitis—Carmustine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Lisdexamfetamine—Headache—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methotrexate—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Lisdexamfetamine—Vomiting—Vincristine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Lisdexamfetamine—Rash—Vincristine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vincristine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Lisdexamfetamine—Headache—Vincristine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Lisdexamfetamine—Nausea—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Lisdexamfetamine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Lisdexamfetamine—Rash—Mitoxantrone—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Lisdexamfetamine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Lisdexamfetamine—Headache—Mitoxantrone—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methotrexate—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methotrexate—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Lisdexamfetamine—Nausea—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Lisdexamfetamine—Nausea—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Lisdexamfetamine—Vision blurred—Methotrexate—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Lisdexamfetamine—Convulsion—Methotrexate—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Lisdexamfetamine—Anorexia—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Lisdexamfetamine—Insomnia—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Lisdexamfetamine—Somnolence—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Lisdexamfetamine—Fatigue—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Lisdexamfetamine—Urticaria—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Lisdexamfetamine—Asthenia—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Lisdexamfetamine—Dizziness—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Lisdexamfetamine—Vomiting—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Lisdexamfetamine—Rash—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Lisdexamfetamine—Headache—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Lisdexamfetamine—Nausea—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
